June 8, 2025
Operating Assets

Navigating Losses and Advancing …

Net Loss: $11.4 million for Q4 2024, compared to $7.8 million in Q4 2023. R&D Expenses: $9.3 million in Q4 2024, up from $6.5 million in Q4 2023. G&A Expenses: $2.9 million in Q4 2024, compared to $2.4 million in Q4 2023. Cash, Cash Equivalents, and Marketable Securities: $107.6 million as of December 31, 2024.

Read More
Operating Assets

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in

Read More